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DNase I from bovine pancreas, DNA (sodium salt from calf thymus, type I, fibers), DMSO 





The synthesis of 1-(pyrrolidin-2-yl)propan-2-one derivatives was conducted according to the 
description in our previous study.[1] 
 
1.3. Evaluation of deoxyribonuclease I inhibition 
 
Compounds were assessed for inhibitory properties against DNase I from bovine pancreas. 
Evaluation of in vitro enzyme inhibition was conducted as spectrophotometric measurement of 
acid-soluble nucleotides formation at 260 nm, according to our previously published procedures[9 
- 13] Studied compounds were assayed for DNase I inhibitory activity at concentration of 200 µM. 
Those exhibiting inhibition greater than 50% at these concentrations were tested in a broader series 
of concentrations to allow calculation of IC50 values. IC50 curves were generated using three 
concentrations of studied compounds (200, 150 and 100 µM). Crystal violet was used as a positive 
control. All experiments were performed in triplicate and averaged. 
 
1.4. In silico molecular and ADMET properties 
 
Physico-chemical and pharmacokinetic properties of proposed compounds were assessed 
using SwissADME online tool,[2,3] together with ADMETlab,[4,5] while OSIRIS DataWarrior 
software[6] was utilized for toxicity prediction. 
 
1.5. In silico PAINS and promiscuity assessment  
 
Web platform HitDexter 2.0 was employed to evaluate similarity to known PAINS and 
predict promiscuity of tested compound.[7,8] 
 
1.6. Molecular docking 
 
1.6.1. Ligand preparation 
 
Examined 1-(pyrrolidin-2-yl)propan-2-ones have been generated using the builder panel in 
the Molecular Operating Environment (MOE) 2019.0101 software.[14] Using the MOE LigX 
module, partial atomic charges were ascribed and possible ionization states were generated at a pH 
of 7.0. The MMFF94x force field was used for optimization and the resulting structures were used 
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for modeling studies. Conformational search was carried out by MOE LowModelMD method 
which performs molecular dynamic perturbations along with low frequency vibrational modes 
with energy window of 7 kcal/mol, and conformational limits of 1000. 
 
1.6.2. Receptor preparation 
 
The X-ray crystallographic structure of DNase I (PDB code: 1DNK), retrieved from the 
Protein Data Bank, was prepared using the Structure Preparation process in MOE. After the 
correction, hydrogens were added and partial charges (Gasteiger methodology) were calculated. 
Energy minimization (AMBER14:EHT, RMS gradient: 0.100) was performed. 
 
1.6.3. Binding site selection 
 
The Site Finder module of the MOE was used to identify possible ligand-binding sites 
within the optimized structure of DNase I. Hydrophobic or hydrophilic alpha spheres served as 
probes denoting zones of tight atom packing. These alpha spheres were utilized to define and rank 
potential ligand-binding sites according to their propensity for ligand binding (PLB) score, which 
was based on the amino acid composition of the pocket.[15] 
 
1.6.4. Docking protocol 
 
The molecular docking study was performed using the MOE to understand the 
ligand/protein interactions in detail. The default Triangle Matcher placement method was used for 
the induced fit docking. GBVI/WSA dG scoring function which estimates the free energy of 
binding of the ligand from a given pose was used to rank the final poses. Each ligand/protein 
complex with lowest relative binding free energy (ΔG) score was selected for further study. 
 
1.7. Molecular dynamics simulation 
 
The molecular dynamics simulation of 1-(pyrrolidin-2-yl)propan-2-ones on DNase I, was 
carried out using the Desmond Molecular Dynamics System (Desmond) 2018.4 software.[16] The 
structure of the added water was based on the simple point charge (SPC) solvent model. The 
system was neutralized with Na+ ions to balance the net charge of the whole simulation box to 
neutral. The final system contained approximately 29500 atoms. The system was passed through 
a 6-step relaxation protocol before molecular dynamics simulations. The relaxed system was 
simulated for 10 ns, using a normal pressure temperature (NPT) ensemble with a Nosé–Hoover 
thermostat at 300 K and Martyna–Tobias–Klein barostat at 1.01325 bar pressure. Atomic 
coordinate data and system energies were recorded every 1 ps. The root mean square deviation 
(RMSD) and root mean square fluctuation (RMSF) of the inhibitor/enzyme complexes were 





2. Supplementary tables 
 
Table S1. Summary of the top five inhibitor-binding sites in DNase I. 
Site Size PLB Hyd Side Residues 
1 34 2.63 9 39 
Asn 7, Arg 9, Glu 39, Glu 78, Arg 111, His 134, Pro 137, 
Asp 168, Asn 170, Tyr 175, Thr 203, Thr 205, Thr 207, Tyr 
211, Asp 251, His 252 
2 10 0.51 13 16 Val 125, Lys 126, Glu 127, His 159, Leu 160, Asn 161, Asp 162, Leu 220 
3 17 0.28 3 19 Tyr 76, Glu 78, Ser 110, Arg 111, His 134, Ser 135, Ala 136, Pro 137, Asn 170 
4 21 0.23 9 14 Pro 137, Ser 138, Asp 139, Ala 140, Val 141, Ala 142, Ser 174, Tyr 175, Gln 180 
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